This inventor holds 1 USPTO granted patent and 1 published patent application and 1 EPO patent. Top assignee: Sanofi. Active years: 2022.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2022
Title: Maximilian Bielohuby: Innovator in Metabolic Liver Disease Treatment
Introduction
Maximilian Bielohuby is a prominent inventor based in Frankfurt am Main, Germany. He has made significant contributions to the field of medical research, particularly in the treatment of metabolic liver diseases. His innovative work focuses on the use of specific GLP-1/glucagon receptor agonists.
Latest Patents
Maximilian Bielohuby holds one patent titled "GLP-1/glucagon receptor agonists in the treatment of fatty liver disease and steatohepatitis." This invention relates to the medical use of these receptor agonists in the prevention and treatment of metabolic liver diseases, specifically targeting non-alcoholic fatty liver disease (NAFLD), non-alcoholic fatty liver (NAFL), non-alcoholic steatohepatitis (NASH), and NAFLD-associated liver fibrosis.
Career Highlights
Maximilian is associated with Sanofi, a leading global healthcare company. His work at Sanofi has allowed him to focus on innovative solutions for complex health issues, particularly in the realm of liver diseases.
Collaborations
He has collaborated with notable colleagues, including Aimo Kannt and Ralf Elvert, to advance research and development in his field.
Conclusion
Maximilian Bielohuby's contributions to the treatment of metabolic liver diseases through his innovative patent highlight his role as a key inventor in the medical field. His work continues to pave the way for advancements in healthcare solutions.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile